Re­gen­eron, GSK see mas­sive spike in Covid-19 mAb de­mand as US de­bates buy­ing more

The Delta vari­ant is busy dri­ving up new Covid-19 cas­es na­tion­wide, ac­cel­er­at­ing de­mand for mon­o­clon­al an­ti­body treat­ments from Re­gen­eron and Glax­o­SmithK­line, which can re­duce hos­pi­tal­iza­tions and deaths if used ap­pro­pri­ate­ly.

Re­gen­eron has seen a dra­mat­ic in­crease in de­mand for its mAb cock­tail of casiriv­imab plus imde­vimab in just the past month. The com­pa­ny has led the mAb field since nab­bing an ear­ly EUA for the drug, which can now be ad­min­is­tered sub­cu­ta­neous­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.